Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06573281 · ClinicalTrials.gov registry record · Phase 1
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
A Phase 1 study of Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 1
- Development phase
- 213
- Enrollment target
- 9
- Study locations
NCT06573281: Active Phase 1 study of Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline.
NCT06573281 is a Phase 1 study of Respiratory Syncytial Virus Infections that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 213 participants, below the 1,081-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06573281, a Phase 1 study of Respiratory Syncytial Virus Infections, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 213 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Conditions Studied
Interventions
- BIOLOGICAL Investigational RSV vaccine 1
- BIOLOGICAL Investigational RSV vaccine 2
- BIOLOGICAL Investigational RSV vaccine 3
- BIOLOGICAL Investigational RSV vaccine 4
- BIOLOGICAL Investigational RSV vaccine 5
Study Locations (9)
Other
- GSK Investigational Site - Madrid
- GSK Investigational Site - Madrid
- GSK Investigational Site - Madrid
California
- GSK Investigational Site - Rolling Hills Estates
Georgia
- GSK Investigational Site - Atlanta
Kansas
- GSK Investigational Site - Lenexa
Nebraska
- GSK Investigational Site - Omaha
New York
- GSK Investigational Site - Rochester
Victoria
- GSK Investigational Site - Camberwell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-04-13 |
| Phase | Phase 1 |
What the registry record for NCT06573281 still lists
NCT06573281 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, below the 1,081-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 5 interventions - of which Investigational RSV vaccine 1 is the first listed.
NCT06573281 lists 9 locations in 7 states (Other, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT06573281 about?
NCT06573281 is a clinical study titled "A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years". The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
What is the current status of trial NCT06573281?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2024-09-30. Estimated completion is 2026-04-13.
What conditions does trial NCT06573281 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT06573281?
The interventions under investigation include: Investigational RSV vaccine 1 (BIOLOGICAL), Investigational RSV vaccine 2 (BIOLOGICAL), Investigational RSV vaccine 3 (BIOLOGICAL), Investigational RSV vaccine 4 (BIOLOGICAL), Investigational RSV vaccine 5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06573281?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06573281 being conducted?
This trial has 9 study locations across California, Georgia, Kansas, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06573281's enrollment target sits among peer trials
213 12th of 21 higher than 10 of 21 other Respiratory Syncytial Virus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of BLB-201 RSV Vaccine in Infants and Children
RECRUITING · Phase 1
-
Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
COMPLETED · Phase 1
-
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
COMPLETED · Phase 1
-
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
COMPLETED · Phase 1
-
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI